在IBD患者中,阿达利穆马布生物类似药的接受度和持续性:一项前性观察性研究
Gabrielle D'Abbundo1, Maria Nachury1, Alice Wartski1
1Department of Gastroenterology, Claude Huriez Hospital, University of Lille 2, Lille, France.
Therapeutic advances in gastroenterology
|April 29, 2025
概括
大多数炎症性肠病患者成功转换为阿达利穆马布 (ADA) 生物类似药,保持临床缓解. 高接受度和积极的患者体验支持生物类似药在IBD管理中的使用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 关于在炎症性肠病 (IBD) 中从阿达利穆马布基准产品 (RP) 转换为生物类似药的数据有限.
- 了解患者接受度和治疗结果对于生物类似药的采用至关重要.
研究的目的:
- 评估在IBD患者中转换为阿达利穆马布生物类似药的接受率.
- 评估持续性,停止治疗的原因,疾病活动的变化以及患者在转换后的感知.
- 确定影响生物类似药物转换不被接受的因素.
主要方法:
- 在法国高等教育中心进行前性研究 (2020年7月至2021年9月).
- 包括IBD门诊患者在阿达利穆马布RP超过6周.
- 患者被建议切换到五种ADA生物类似药,收集了关于接受,持久性,疾病活性和感知的数据.
主要成果:
- 91.8%的患者接受了转换;只有对仿制药的不良看法与不接受有关.
- 在12个月后,初始生物类似药的持续性为60.4%,没有停止治疗的生存率为71%;
- 在12个月内,临床缓解维持在90.4%;65.8%报告了积极的切换体验.
结论:
- 在IBD患者中切换到阿达利穆马布生物仿制药显示出高接受度和良好的结果.
- 持续的疗效,良好的治疗持续性和积极的患者感知支持生物类似药的使用.
- 阿达利穆马布生物仿制药是IBD管理的可行治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
100
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
100
Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79
Drugs for Treatment of Ulcerative Colitis in IBD
102
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
102
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
223
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
223
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
86
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
86


